Allogene Therapeutics (ALLO) Other financing activities (2024 - 2025)
Allogene Therapeutics recorded quarterly Other financing activities of $3.6 million in Q2 2025, up 6.21% quarter-over-quarter from $3.4 million in Q1 2025, and up 56.05% year-over-year from $2.3 million in Q2 2024.
Allogene Therapeutics' Other financing activities history runs 2 years deep, the most recent figure standing at $3.6 million for Q2 2025.
- In Q2 2025, Other financing activities rose 56.05% year-over-year to $3.6 million; the TTM figure through Mar 2026 stood at $3.6 million (down 36.8% YoY), while the FY2025 annual figure was $6.9 million, up 202.98% from the prior year.
- Other financing activities came in at $3.6 million for Q2 2025 at Allogene Therapeutics, up from $3.4 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $3.6 million in Q2 2025 to a low of $2.3 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Allogene Therapeutics | 521.43 Mn | 521.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 3.56 Mn |
| Jun 30, 2025 | 3.56 Mn |
| Mar 31, 2025 | 3.35 Mn |
| Mar 31, 2025 | 3.35 Mn |
| Jun 30, 2024 | 2.28 Mn |
| Jun 30, 2024 | 2.28 Mn |